Robert E. Davis

Dr. Davis has served as Senior Vice President, Chief Scientific Officer since November 2015. Previously, Dr. Davis served as President and CEO of 3-D Pharmaceutical Consultants, providing consulting services to the Company from December 2005 to November 2015. From December 2000 until November 2005, Dr. Davis served as the Executive Vice President, Research and Development at ACADIA Pharmaceuticals. From January 1994 until October 2000, Dr. Davis held various positions at MitoKor, a development stage biotechnology company focused on the design and development of drug therapies for mitochondrial diseases, serving at various times as its President, Chief Executive Officer, and Chief Scientific Officer. Earlier, Dr. Davis held various positions at Parke-Davis Pharmaceutical Research, Warner-Lambert. Earlier in his career, he participated in the discovery and development of Cognex, the first drug approved for treating Alzheimer’s disease; Neurontin, the first drug approved for treating neuropathic pain; and Nuplazid, the first drug approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Dr. Davis received his B.S., M.S., and Ph.D. in Psychobiology from the University of Illinois.